PXMTF (PHAXIAM Therapeutics) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2023)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics LT-Debt-to-Total-Asset?

PHAXIAM Therapeutics PXMTF 38 LT-Debt-to-Total-Asset is 0.00 as of Sep. 2023. GuruFocus rates PXMTF with a GF Score™ of 38/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PHAXIAM Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

PHAXIAM Therapeutics's long-term debt to total assets ratio declined from Jun. 2022 (0.05) to Sep. 2023 (0.00). It may suggest that PHAXIAM Therapeutics is progressively becoming less dependent on debt to grow their business.

PHAXIAM Therapeutics  (OTCPK:PXMTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PHAXIAM Therapeutics LT-Debt-to-Total-Asset Related Terms

PHAXIAM Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics LT-Debt-to-Total-Asset Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.11 0.29 0.35 0.22

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.00 0.22 0.04 0.00
PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics LT-Debt-to-Total-Asset Calculation

PHAXIAM Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=10.834/48.529
=

PHAXIAM Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
PHAXIAM Therapeutics (PXMTF) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' LT-Debt-to-Total-Asset too high?
PHAXIAM Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
PHAXIAM Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price